Foghorn Therapeutics Inc.
NASDAQ:FHTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Foghorn Therapeutics Inc.
Accounts Payable
Foghorn Therapeutics Inc.
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Foghorn Therapeutics Inc.
NASDAQ:FHTX
|
Accounts Payable
$4.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$34.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$715m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.9B
|
CAGR 3-Years
134%
|
CAGR 5-Years
91%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
Foghorn Therapeutics Inc.
Glance View
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.
See Also
What is Foghorn Therapeutics Inc.'s Accounts Payable?
Accounts Payable
4.3m
USD
Based on the financial report for Dec 31, 2025, Foghorn Therapeutics Inc.'s Accounts Payable amounts to 4.3m USD.
What is Foghorn Therapeutics Inc.'s Accounts Payable growth rate?
Accounts Payable CAGR 5Y
3%
Over the last year, the Accounts Payable growth was 13%. The average annual Accounts Payable growth rates for Foghorn Therapeutics Inc. have been -8% over the past three years , 3% over the past five years .
